GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Beneish M-Score

ARTV (Artiva Biotherapeutics) Beneish M-Score : 0.00 (As of Mar. 16, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Artiva Biotherapeutics's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Artiva Biotherapeutics was 6.45. The lowest was 6.45. And the median was 6.45.


Artiva Biotherapeutics Beneish M-Score Historical Data

The historical data trend for Artiva Biotherapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Beneish M-Score Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - - 6.45

Artiva Biotherapeutics Quarterly Data
Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.45 - - -

Competitive Comparison of Artiva Biotherapeutics's Beneish M-Score

For the Biotechnology subindustry, Artiva Biotherapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artiva Biotherapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's Beneish M-Score falls into.



Artiva Biotherapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Artiva Biotherapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $0.70 Mil.
Revenue was 0 + 0 + 0.251 + 2.35 = $2.60 Mil.
Gross Profit was 0 + 0 + 0.251 + 2.35 = $2.60 Mil.
Total Current Assets was $150.57 Mil.
Total Assets was $225.60 Mil.
Property, Plant and Equipment(Net PPE) was $21.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.41 Mil.
Selling, General, & Admin. Expense(SGA) was $15.42 Mil.
Total Current Liabilities was $13.29 Mil.
Long-Term Debt & Capital Lease Obligation was $11.24 Mil.
Net Income was -17.472 + -14.537 + -13.963 + -10.974 = $-56.95 Mil.
Non Operating Income was -0.983 + 2.329 + -0.121 + 0.485 = $1.71 Mil.
Cash Flow from Operations was -11.611 + -13.685 + -15.086 + -10.675 = $-51.06 Mil.
Total Receivables was $0.00 Mil.
Revenue was 26.656 + 0 + 0.989 + 0 = $27.65 Mil.
Gross Profit was 26.656 + 0 + 0.989 + 0 = $27.65 Mil.
Total Current Assets was $0.00 Mil.
Total Assets was $0.00 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.67 Mil.
Selling, General, & Admin. Expense(SGA) was $10.75 Mil.
Total Current Liabilities was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.701 / 2.601) / (0 / 27.645)
=0.269512 / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(27.645 / 27.645) / (2.601 / 2.601)
=1 / 1
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (150.565 + 21.509) / 225.596) / (1 - (0 + 0) / 0)
=0.237247 /
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.601 / 27.645
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.672 / (1.672 + 0)) / (2.411 / (2.411 + 21.509))
=1 / 0.100794
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(15.422 / 2.601) / (10.745 / 27.645)
=5.929258 / 0.388678
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11.235 + 13.292) / 225.596) / ((0 + 0) / 0)
=0.108721 /
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-56.946 - 1.71 - -51.057) / 225.596
=-0.033684

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Artiva Biotherapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Artiva Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.